Dupilumab therapy for atopic dermatitis and aneurysmal subarachnoid hemorrhage: A case report and literature review
Article information
Abstract
Dupilumab is a human IgG4 monoclonal antibody that inhibits IL-4 and IL-13 signaling through IL-4Rα, thereby reducing Th2-mediated inflammation. Although it has demonstrated significant efficacy in the treatment of atopic dermatitis, its long-term vascular safety profile remains incompletely understood. We report a case of a 27-year-old male who developed sudden headache after physical exertion while receiving Dupilumab therapy for two years. Brain computed tomography revealed subarachnoid hemorrhage, and angiography demonstrated a ruptured dissecting aneurysm in the distal posterior cerebral artery. The patient underwent successful stent-assisted coil embolization, and follow-up imaging confirmed complete occlusion without neurological deficits. Dupilumab therapy was discontinued after the procedure. Although Dupilumab effectively suppresses allergic inflammation, chronic inhibition of the anti-inflammatory cytokines IL-4 and IL-13 signaling may theoretically influence vascular homeostasis through alterations in inflammatory pathways. Such mechanisms could potentially affect endothelial stability or thrombo-inflammatory balance. Given the inherent limitations of a single case report, a causal relationship cannot be established. However, this case raises the possibility of an association between prolonged Dupilumab therapy and cerebrovascular vulnerability, highlighting the need for further investigation into the vascular effects of long-term cytokine inhibition.
INTRODUCTION
Stroke in young adults exhibits distinct clinical characteristics compared with those observed in middle-aged and elderly populations. In particular, the association with traditional vascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, and smoking tends to be relatively low. In contrast, causes that are rare in older individuals are more frequently observed in younger adults, and the etiology of stroke in this population is markedly heterogeneous. Moreover, in many cases, the precise cause remains unidentified [10].
Posterior cerebral artery (PCA) aneurysms are relatively rare, comprising approximately 0.7% to 2.3% of all intracranial aneurysms [13] and roughly 7% of those located in the posterior circulation [6]. The majority of PCA aneurysms (approximately 90%) arise in the P1 and P2 segments, while aneurysms involving the more distal P3 and P4 segments are uncommon [8]. These distal PCA aneurysms are particularly rare compared with proximal PCA aneurysms and have distinct clinical characteristics that warrant careful consideration.
Comprehensive analyses of posterior cerebral artery aneurysms have demonstrated that P3 segment aneurysms, particularly those with fusiform morphology, are rare, comprising only about 2% to 3 % of all posterior cerebral artery aneurysms. Despite their rarity, several studies have suggested that distal PCA aneurysms exhibit a relatively high propensity for rupture. Reported rupture rates in distal lesions reach up to 75% to 100%, which markedly exceeds the approximately 27% rupture rate reported for proximal PCA aneurysms [3,4]. These findings highlight the clinical significance of distal PCA aneurysms and emphasize the importance of recognizing and reporting such cases.
The disproportionately high rupture rate observed in distal PCA aneurysms remains poorly understood. One possible explanation is their location in low-flow regions with inherently thinner vessel walls, which may predispose them to rupture [5].
In this context, we report a case of aneurysmal subarachnoid hemorrhage caused by rupture of a fusiform aneurysm in the distal P3 segment of the posterior cerebral artery in a young adult receiving long-term Dupilumab therapy for atopic dermatitis. Given the inherent limitations of a single case report, this report does not aim to establish Dupilumab as a causal risk factor but rather to describe a possible association and explore potential mechanisms that may warrant further investigation.
CASE DESCRIPTION
A 27-year-old man presented to the emergency department with a sudden onset of headache after physical exertion at home. He was ambulatory upon arrival and did not report any additional symptoms. Neurological examination revealed no focal deficits. The patient had a known history of atopic dermatitis and had been receiving Dupilumab injections every two weeks since August 30, 2022. His most recent 300 mg subcutaneous injection was administered on July 30, 2024, approximately two weeks prior to the onset of symptoms, with a total of 48 doses administered before presentation.
Brain computed tomography (CT) performed in the emergency department revealed a subarachnoid hemorrhage (SAH) (Fig. 1A). Subsequent transfemoral cerebral angiography (TFCA) demonstrated a ruptured aneurysm located in the right distal posterior cerebral artery (PCA) (Fig. 1B). The aneurysm appeared irregular and fusiform in morphology, and was located in the distal P3 segment of the parieto-occipital branch of the posterior cerebral artery (Fig. 1B). Angiographic findings demonstrated tapered stenosis with focal dilatation, producing a pearland-string appearance suggestive of a dissecting aneurysm (Fig. 1B). Emergent stent-assisted coil embolization was performed (Fig. 1C). The final angiogram confirmed complete occlusion of the aneurysm without residual filling, and the procedure was completed without any complications (Fig. 1D).
(A) Initial brain computed tomography presented diffuse subarachnoid hemorrhage. (B) The fusiform aneurysm was seen on distal P3 at parieto-occipital artery. (C) Coil embolization was performed with stent assistance and postprocedural angiogram showed the complete occlusion without any complication. (D) No abnormality was shown in the follow up angiogram.
Follow-up TFCA was performed to evaluate the status of the treated dissecting aneurysm, and no abnormal findings were observed. Additional vessel wall magnetic resonance imaging (MRI) also showed no abnormalities. The patient remained neurologically stable without clinical deterioration and was discharged on postoperative day 13. At the one-month outpatient follow-up, the patient reported no neurological symptoms. Dupilumab therapy was discontinued after the procedure as part of the clinical management plan.
DISCUSSION
Previous studies have suggested a potential association between atopic dermatitis (AD) and ischemic stroke in adults, with in vitro research indicating that impaired fibrinolysis may contribute to increased platelet activation and fibrin clot formation [5,7,11]. However, atopic dermatitis has not been previously reported as a causative factor for hemorrhagic stroke in young adults.
In the present case, a subarachnoid hemorrhage occurred due to rupture of a fusiform aneurysm in the distal P3 segment of the posterior cerebral artery in a young patient without conventional vascular risk factors. Although aggressive physical exertion may have contributed to arterial dissection, the possible influence of long-term Dupilumab therapy cannot be excluded. Importantly, a causal relationship between Dupilumab therapy and aneurysmal rupture cannot be established based on a single case report. Rather, this case suggests only a possible temporal association that warrants further investigation.
To better contextualize the present case, we reviewed previously reported cerebrovascular events temporally associated with Dupilumab therapy and summarized them in Table 1. The available literature suggests that such events remain extremely rare and have predominantly involved ischemic mechanisms. In contrast, hemorrhagic cerebrovascular events associated with Dupilumab have not been clearly documented, making the present case particularly noteworthy.
Alternative explanations should also be considered. The aneurysm may have represented a preexisting vascular lesion that ruptured spontaneously, which is a recognized mechanism in distal PCA aneurysms. In addition, underlying inflammatory conditions such as atopic dermatitis itself may contribute to vascular dysfunction through chronic immune activation and systemic inflammatory reponses.
To explore potential mechanisms underlying this possible association, several hypotheses may be considered. The first hypothesis involves vascular endothelial dysfunction [5]. As previously mentioned, interleukin-4 (IL-4) and interleukin-13 (IL-13) are key cytokines in the Th2-mediated immune responses and are primarily associated with allergic inflammation. These cytokines have also been reported to exert regulatory and anti-inflammatory effects on vascular endothelial cells [9].
IL-4 and IL-13 interact with pro-inflammatory cytokines such as IL-1β and TNF-α to modulate the immune response. When these signaling pathways are inhibited by Dupilumab, the regulatory effects of IL-4 and IL-13 on endothelial cells may theoretically be reduced. This could potentially result in endothelial dysfunction through increased activity of pro-inflammatory mediators such as TNF-α.
Previous studies have shown that IL-4 suppresses the secretion of IL-1β and TNF-α in human monocytes, suggesting an important role of IL-4 in immune regulation and inflammatory control. Therefore, inhibition of IL-4 and IL-13 signaling may theoretically lead to increased vascular permeability and potential weakening of vascular structures [12].
The second hypothesis involves increased vascular inflammation [5]. Inhibition of IL-4 and IL-13 signaling may promote M1 macrophage activation, thereby favoring a pro-inflammatory immune response. Although this mechanism has not been directly demonstrated in cerebrovascular disease, it could theoretically contribute to vascular wall vulnerability or exacerbate pre-existing vascular abnormalities.
Inflammation is known to play a central pathogenic role in the development of cardiovascular and cerebrovascular disease [1]. Anti-inflammatory cytokines such as IL-4 and IL-13 suppress the release of histamine and other inflammatory mediators and reduce the production of pro-inflammatory cytokines including IL-1β and TNF-α.
TNF-α and IL-1β are also key inflammatory mediators involved in secondary brain injury following hemorrhagic stroke. Their levels have been shown to increase significantly after the onset of hemorrhage [14]. Elevated TNF-α may exacerbate brain injury by promoting cerebral edema and neurological dysfunction [14], while increased IL-1β has been associated with blood-brain barrier (BBB) disruption and severe cerebral edema.
The third hypothesis involves a potential imbalance between thrombosis and hemostasis [5]. IL-4 and IL-13 have been reported to contribute to the maintenance of anticoagulant properties in vascular endothelium. Therefore, inhibition of these cytokines may theoretically influence thrombo-inflammatory pathways that could affect vascular stability.
In addition to these inflammatory mechanisms, chronic inhibition of IL-4 and IL-13 signaling may also influence vascular remodeling and structural integrity of the arterial wall [1,7]. IL-4 and IL-13 have been implicated in tissue repair processes and extracellular matrix regulation [1,7]. Therefore, prolonged blockade of these cytokines by Dupilumab could theoretically impair vascular repair mechanisms. Such alterations may affect extracellular matrix homeostasis, potentially leading to structural changes in the vascular wall, including thinning of the internal elastic lamina or alterations in collagen synthesis. These changes could contribute to increased susceptibility of the arterial wall to mechanical stress and may predispose vulnerable vessels to aneurysmal progression or rupture. Although direct evidence for this mechanism in cerebrovascular disease remains limited, such a hypothesis may provide a biologically plausible explanation for the potential interaction between chronic IL-4/IL-13 inhibition and vascular wall vulnerability.
In the present patient, laboratory evaluation for systemic vasculitis was performed to assess the possibility of an underlying systemic vascular disorder, and all results were within normal ranges. Although these findings do not completely exclude subtle vascular vulnerability, they reduce the likelihood of an underlying systemic vasculitic process contributing to the aneurysmal rupture. Taken together, it is possible that aggressive physical exertion may have acted as a mechanical trigger for arterial injury, while long-term Dupilumab therapy may have influenced vascular homeostasis, potentially contributing to vascular wall vulnerability.
Taken together, these mechanisms remain speculative and require further experimental and clinical validation. The present case does not establish Dupilumab as a definitive risk factor for aneurysmal subarachnoid hemorrhage. Instead, it highlights a possible association between prolonged Dupilumab therapy and cerebrovascular vulnerability in a young patient. Further studies are needed to better understand the vascular effects of long-term IL-4 and IL-13 signaling inhibition and to determine whether any causal relationship exists.
CONCLUSIONS
This case describes aneurysmal subarachnoid hemorrhage caused by rupture of a distal posterior cerebral artery aneurysm in a young adult receiving long-term Dupilumab therapy for atopic dermatitis. Given the inherent limitations of a single case report, a causal relationship between Dupilumab therapy and hemorrhagic cerebrovascular events cannot be established. However, this case raises the possibility of a potential association between prolonged Dupilumab exposure and cerebrovascular vulnerability. Further studies are required to better understand the vascular safety profile of long-term Dupilumab therapy and to clarify whether any meaningful relationship with cerebrovascular events exists.
Notes
ACKNOWLEDGMENTS
This study was supported by the 2025 Education, Research, and Student Guidance Grant funded by Jeju National University.
Informed consent
The patient provided written informed consent for participation and publication.
Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
